A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE).

The study only randomised two patients and so could not address the benefits of intravenous immunoglobulin, however they identified several recruitment barriers which would need to be overcome in future trials

http://ift.tt/2sQOay0